Cortisol And Cushing's Syndrome Science

---

Table of Contents

1. What Is Cushing's Syndrome? Defining the Cortisol Excess Disease
2. The Science of Cortisol: How the HPA Axis Works
3. Cushing's Syndrome vs. Cushing's Disease: Key Differences
4. What Causes Pathological Cortisol Elevation?
5. Recognizing the Symptoms: First Signs and Advanced Presentation
6. How Cushing's Syndrome Is Diagnosed in 2024–2026 Practice
7. Which Cortisol Tests Are Most Accurate?
8. Risks of Untreated High Cortisol: What the Research Shows
9. Treatment Options for Cushing's Syndrome
10. Can Stress Alone Cause Cushing's Syndrome?
11. Emerging Research in Cushing's Syndrome (2024–2025)
12. Frequently Asked Questions
13. Key Takeaways

---

Medical Disclaimer: This article is written for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, testing, and treatment of any medical condition.

---

What Is Cushing's Syndrome? Defining the Cortisol Excess Disease

Cushing's syndrome is one of the most clinically complex endocrine disorders known to modern medicine. At its core, it is a cortisol excess disease — a condition defined by the prolonged, pathological exposure of the body's tissues to abnormally elevated cortisol concentrations. Understanding the science behind Cushing's syndrome cortisol dynamics requires a grounding in what cortisol is, what it does when it functions normally, and what goes wrong when it is present in excess over sustained periods of time.

Cortisol is a glucocorticoid steroid hormone produced by the adrenal cortex, specifically the zona fasciculata. In a healthy physiological state, cortisol is released in a diurnal pattern — highest in the morning and lowest at night — and serves a remarkable range of functions. It regulates glucose metabolism, modulates immune responses, maintains blood pressure, and governs the body's response to physical and psychological stress. These are essential, life-sustaining processes. The problem with Cushing's syndrome is not the existence of cortisol itself; it is the disruption of the tightly regulated system that keeps cortisol production within safe boundaries.

When cortisol Cushing's dynamics are at play — meaning the normal regulatory mechanisms fail — the consequences are systemic and progressive. Every major organ system in the body is affected, from the cardiovascular system to the brain, from the bones to the immune system. This is why Cushing's syndrome, though rare in its endogenous form, carries significant morbidity and mortality when left undiagnosed or untreated.

According to a 2023 PubMed review titled "Cushing Syndrome: A Review," the incidence of endogenous Cushing syndrome is estimated at 2 to 8 people per million annually. This makes it a rare disease in the strictest epidemiological sense, but one with outsized clinical importance because of how profoundly it disrupts virtually every body system. Notably, a 2023 Medscape overview clarified that more than 99% of all Cushing syndrome cases are actually attributable to exogenous glucocorticoid exposure — meaning the vast majority of people who develop hypercortisolism do so as a result of taking prescribed steroid medications, not from internal tumors or glandular dysfunction.

This epidemiological reality shapes how clinicians think about the condition. The cortisol disease excess that most patients experience is iatrogenic — caused by medical treatment — while the endogenous forms, though far rarer, represent a distinct and often diagnostically challenging disease category that has driven decades of endocrinology research.

---

---

The Science of Cortisol: How the HPA Axis Works

To fully appreciate what goes wrong in Cushing's syndrome, you need to understand what goes right in a healthy system. The hypothalamic-pituitary-adrenal (HPA) axis is the elegant, multi-tiered hormonal cascade that governs cortisol production. The Cushing's HPA relationship is central to understanding why this disease exists and how it manifests so differently depending on where the dysfunction originates.

The Three Tiers of the HPA Axis

1. The Hypothalamus The hypothalamus, located deep in the brain, acts as the master regulator of the HPA axis. When the body perceives stress — whether physical, psychological, or physiological — neurons in the hypothalamus synthesize and release corticotropin-releasing hormone (CRH). CRH travels through the hypothalamic-pituitary portal blood vessels to reach the anterior pituitary gland.

2. The Anterior Pituitary In response to CRH, specialized cells in the anterior pituitary gland called corticotrophs synthesize and release adrenocorticotropic hormone (ACTH), also known as corticotropin. ACTH enters the general circulation and travels to the adrenal glands, which sit atop the kidneys.

3. The Adrenal Cortex ACTH binds to receptors on the adrenal cortex and stimulates the synthesis and secretion of cortisol. Cortisol then circulates through the body, exerting its wide-ranging metabolic and immunological effects.

The Negative Feedback Loop

What keeps this system in balance is a negative feedback mechanism. As cortisol levels rise in the bloodstream, the elevated cortisol signals back to both the hypothalamus and the anterior pituitary to reduce CRH and ACTH secretion, respectively. This feedback loop ensures that cortisol production is self-limiting — when enough cortisol is present, the system turns itself down.

In Cushing's syndrome, this feedback mechanism is disrupted. Depending on the underlying cause, either:

• The pituitary produces excessive ACTH despite normal or high cortisol levels (as in Cushing's disease caused by a pituitary adenoma)
• An adrenal tumor produces cortisol autonomously, independent of ACTH regulation
• An ectopic tumor elsewhere in the body secretes ACTH or CRH, bypassing normal regulatory controls
• Exogenous glucocorticoids suppress the HPA axis while simultaneously producing the phenotypic effects of hypercortisolism

Why the Diurnal Rhythm Matters

In healthy individuals, cortisol follows a circadian rhythm: levels peak approximately 30 to 45 minutes after waking (the cortisol awakening response) and decline throughout the day, reaching their nadir around midnight. This rhythm is coordinated by the suprachiasmatic nucleus of the hypothalamus and the HPA axis.

One of the hallmark features of pathological cortisol elevation in Cushing's syndrome is the loss of this diurnal rhythm. Patients with active Cushing's syndrome often have elevated late-night cortisol levels that fail to show the normal nighttime suppression. This is clinically significant because late-night salivary cortisol measurement has become one of the recommended first-line screening tests for the condition.

---

Cushing's Syndrome vs. Cushing's Disease: Key Differences

One of the most common points of confusion in both clinical practice and public understanding is the difference between Cushing's syndrome and Cushing's disease. These are related but distinct diagnoses, and understanding the distinction is fundamental to understanding the cortisol excess disease landscape.

Cushing's Syndrome: The Umbrella Term

Cushing's syndrome is the broader, umbrella term that describes the clinical state of prolonged exposure to excess cortisol, regardless of the underlying cause. Any patient with chronically elevated cortisol — whether from a tumor, a medication, or another source — technically has Cushing's syndrome if they develop the characteristic clinical features.

The term was coined in honor of Harvey Cushing, the American neurosurgeon who first described the clinical syndrome in 1932 based on observations of patients with pituitary tumors and characteristic physical features.

Cushing's Disease: The Specific Pituitary Form

Cushing's disease is a specific subtype of Cushing's syndrome. It refers exclusively to ACTH-dependent Cushing's syndrome caused by an ACTH-secreting pituitary adenoma (a tumor of the pituitary gland). This distinction matters enormously for treatment, because the primary intervention for Cushing's disease is surgical removal of the pituitary tumor, whereas other causes of Cushing's syndrome require entirely different therapeutic approaches.

Cushing's disease accounts for approximately 70 to 80% of endogenous ACTH-dependent Cushing's syndrome cases in adults, making it the most common endogenous cause. The pituitary adenomas responsible are usually microadenomas — very small tumors (less than 10mm in diameter) — which makes them notoriously difficult to visualize on imaging studies.

Summary Table: Syndrome vs. Disease

| Feature | Cushing's Syndrome | Cushing's Disease | |---|---|---| | Scope | All causes of cortisol excess | Pituitary adenoma specifically | | ACTH status | Dependent or independent | ACTH-dependent (elevated) | | Primary cause | Multiple (see below) | Pituitary corticotroph adenoma | | Primary treatment | Varies by cause | Transsphenoidal surgery | | Prevalence | Broader category | ~70–80% of endogenous cases |

Understanding the Cushing's syndrome cortisol picture requires recognizing that the same biochemical endpoint — excess circulating cortisol — can arise from fundamentally different pathological origins, and that the origin dictates the treatment strategy entirely.

---

What Causes Pathological Cortisol Elevation?

The causes of pathological cortisol elevation in Cushing's syndrome fall into two major categories: exogenous (from outside the body) and endogenous (from within the body). Understanding this distinction is the foundation of the clinical approach to every patient presenting with suspected hypercortisolism.

Exogenous Causes: The Most Common Culprit

As noted by the 2023 Medscape overview, more than 99% of all Cushing syndrome cases are due to exogenous glucocorticoid exposure. This statistic is staggering and has profound implications for how broadly the concept of cortisol disease excess should be considered in clinical practice.

Exogenous glucocorticoids that can cause Cushing's syndrome include:

• Oral corticosteroids (prednisone, prednisolone, dexamethasone, methylprednisolone) — the most common culprits
• Inhaled corticosteroids (budesonide, fluticasone) — particularly in high doses or with prolonged use
• Topical corticosteroids (hydrocortisone cream, betamethasone) — especially potent formulations applied to large body surface areas
• Intra-articular corticosteroid injections — when performed frequently
• Epidural corticosteroid injections
• Intraocular corticosteroids
• Nasal corticosteroid sprays — in high doses

The clinical syndrome that results from exogenous glucocorticoids is called iatrogenic Cushing's syndrome, and it is biochemically characterized by elevated cortisol activity with suppressed ACTH and endogenous cortisol production (because the exogenous steroids suppress the HPA axis). This has important diagnostic implications.

Endogenous Causes: ACTH-Dependent vs. ACTH-Independent

Endogenous Cushing's syndrome is subdivided based on whether excess cortisol production is driven by ACTH or occurs independently of ACTH.

ACTH-Dependent Causes (~80–85% of Endogenous Cases)

1. Cushing's Disease (Pituitary ACTH Excess) A corticotroph adenoma in the anterior pituitary secretes excessive ACTH, which then over-stimulates the adrenal glands to produce excess cortisol. The negative feedback loop is partially but not completely intact — cortisol does partially suppress the tumor, but not at normal physiological levels.

2. Ectopic ACTH Syndrome Certain non-pituitary tumors can produce ACTH autonomously, completely bypassing normal hypothalamic-pituitary regulation. Common tumors associated with ectopic ACTH production include:

• Small cell lung carcinoma (most common)
• Bronchial carcinoid tumors
• Thymic carcinoid tumors
• Pancreatic neuroendocrine tumors
• Pheochromocytoma (rare)
• Medullary thyroid carcinoma (rare)

Ectopic ACTH syndrome often presents with more severe and rapidly progressive hypercortisolism than Cushing's disease, because the ectopic source is not subject to any feedback regulation.

3. Ectopic CRH Secretion Extremely rare tumors can secrete CRH, which then drives pituitary ACTH release and subsequent adrenal cortisol overproduction. This mimics Cushing's disease biochemically but originates outside the pituitary.

ACTH-Independent Causes (~15–20% of Endogenous Cases)

1. Adrenal Adenoma A benign cortisol-secreting tumor (adenoma) of the adrenal cortex produces cortisol autonomously, independent of ACTH stimulation. ACTH levels are suppressed because of the high cortisol feedback to the pituitary.

2. Adrenal Carcinoma Adrenocortical carcinoma is a rare but aggressive malignancy that can produce large amounts of cortisol. It often also co-secretes other steroid hormones (androgens, mineralocorticoids), which contributes to a more complex clinical picture.

3. ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH) Both adrenal glands develop multiple nodules and produce excessive cortisol autonomously. This is caused by aberrant expression of hormone receptors (such as receptors for gastric inhibitory polypeptide, vasopressin, or catecholamines) in adrenal cortex cells, leading to inappropriate cortisol stimulation.

4. Primary Pigmented Nodular Adrenocortical Disease (PPNAD) A rare genetic cause often associated with Carney Complex, in which small pigmented nodules form throughout both adrenal glands and produce excess cortisol independently.

---

---

Recognizing the Symptoms: First Signs and Advanced Presentation

The clinical presentation of Cushing's syndrome cortisol excess is notoriously heterogeneous. Because cortisol affects virtually every organ system, the symptom constellation can overlap significantly with other common conditions, including obesity, metabolic syndrome, depression, and polycystic ovary syndrome. This overlap is one of the primary reasons that Cushing's syndrome is frequently diagnosed late — often years after symptoms first appear.

Early and Common Symptoms

The first symptoms of Cushing's syndrome are often subtle and nonspecific. They may include:

• Weight gain, particularly in the trunk and abdomen (central obesity), with relatively sparing of the limbs
• Fatigue and generalized weakness
• Mood changes, including irritability, depression, or anxiety
• Cognitive difficulties, including difficulty concentrating and memory problems
• Increased appetite
• Sleep disturbances
• Menstrual irregularities in women (oligomenorrhea or amenorrhea)
• Decreased libido in both sexes
• Hypertension (high blood pressure) that may be difficult to control

The Classic Cushingoid Features

As the condition progresses and cortisol Cushing's exposure becomes more sustained, more distinctive clinical features emerge:

Fat Redistribution:

• Central obesity — accumulation of fat in the abdomen, particularly visceral fat
• Moon face (facial rounding) — fat deposition in the cheeks and face, creating a characteristic rounded appearance
• Buffalo hump (dorsocervical fat pad) — fat accumulation at the back of the neck and upper back
• Supraclavicular fat pads — fat deposits above the collar bones

Skin Changes:

• Striae (stretch marks) — typically purple or reddish-purple, wide (greater than 1 cm), and found on the abdomen, flanks, breasts, axillae, or thighs. These differ from ordinary white or silver stretch marks.
• Skin thinning — the skin becomes fragile, transparent-appearing, and bruises easily
• Easy bruising — even with minimal trauma
• Poor wound healing
• Acne
• Hyperpigmentation — more characteristic of ACTH-dependent forms, particularly ectopic ACTH syndrome, where very high ACTH levels stimulate melanocortin receptors

Musculoskeletal:

• Proximal muscle weakness — difficulty climbing stairs, rising from a chair, or lifting arms above the head; weakness is more prominent in the thigh and shoulder muscles
• Osteoporosis — cortisol suppresses bone formation and increases bone resorption, leading to reduced bone density and increased fracture risk
• Pathological fractures — particularly of vertebral bodies and ribs

• Hyperglycemia / Diabetes mellitus — cortisol promotes gluconeogenesis and induces insulin resistance
• Dyslipidemia — elevated triglycerides and LDL cholesterol
• Hypokalemia — particularly in ectopic ACTH syndrome, where cortisol's mineralocorticoid activity can cause potassium wasting

Reproductive and Sexual:

• Hirsutism in women (excess hair growth on face, chest, abdomen)
• Clitoral enlargement (virilization, more common with adrenal carcinoma)
• Erectile dysfunction in men
• Infertility in both sexes

Neuropsychiatric:

• Depression — one of the most prevalent psychiatric manifestations of pathological cortisol elevation
• Anxiety and panic attacks
• Psychosis (in severe cases)
• Cognitive impairment — particularly affecting declarative memory and executive function, mediated by cortisol's effects on the hippocampus

Immunological:

• Increased susceptibility to infections — cortisol suppresses immune function, leading to more frequent and severe infections, including opportunistic infections in severe hypercortisolism

Symptoms in Children

Hypercortisolism in children presents with some distinctive features. The most important is growth retardation — cortisol excess suppresses growth hormone secretion and IGF-1 activity, halting linear growth. A child with Cushing's syndrome may gain weight while failing to grow in height, which is a clinically important diagnostic clue. Central obesity and delayed puberty are also common pediatric presentations.

Symptom Severity and Speed of Onset

The speed and severity of symptom onset in cortisol disease excess varies significantly by cause. Ectopic ACTH syndrome from aggressive tumors like small cell lung carcinoma can produce rapid-onset, severe hypercortisolism — sometimes with profound hypokalemia, muscle weakness, and hyperglycemia — that develops over weeks to months. In contrast, Cushing's disease from a small pituitary microadenoma may cause slowly progressive symptoms over years, making recognition even more challenging.

---

How Cushing's Syndrome Is Diagnosed in 2024–2026 Practice

The diagnosis of Cushing's syndrome is a multi-step process. It begins with clinical suspicion, proceeds through biochemical confirmation of hypercortisolism, and then requires determining the underlying cause. Each step has its own complexity and diagnostic pitfalls.

Step 1: Establishing Clinical Suspicion

Not every patient with obesity, hypertension, and fatigue needs Cushing's workup. Clinical suspicion is appropriately raised when patients have:

• Multiple features typical of hypercortisolism (particularly the more discriminating features like purple striae, proximal myopathy, easy bruising, or unusual fat distribution)
• Unexpected findings for their age group (e.g., osteoporosis in a young adult, or hypertension in a child)
• Incidentally discovered adrenal mass (adrenal incidentaloma) on imaging
• Poor response to treatment of presumed metabolic syndrome components

Step 2: Biochemical Screening for Hypercortisolism

The 2024 Endotext guidelines recommend three first-line screening tests for Cushing's syndrome:

1. 1 mg Overnight Dexamethasone Suppression Test (DST)
2. Late-Night Salivary Cortisol (LNSC)
3. 24-Hour Urinary Free Cortisol (UFC)

For salivary cortisol and urinary free cortisol, at least 2 samples or collections are recommended to improve diagnostic reliability, given the variability inherent in these measurements. The rationale is that a single measurement may miss episodic or cyclical hypercortisolism, which is a recognized phenomenon particularly in Cushing's disease.

1 mg Overnight DST: The patient takes 1 mg of dexamethasone at 11 PM, and serum cortisol is measured at 8 AM the following morning. In healthy individuals, dexamethasone suppresses cortisol to below 1.8 μg/dL (50 nmol/L). Failure to suppress cortisol below this threshold is a positive screen. This test has high sensitivity (around 95–98%) but lower specificity — meaning false positives are common in patients with depression, alcoholism, obesity, or those taking medications affecting dexamethasone metabolism (notably CYP3A4 inducers).

Late-Night Salivary Cortisol: This test exploits the loss of diurnal cortisol rhythm in Cushing's syndrome. Saliva is collected around midnight, when cortisol should be at its daily nadir. Elevated late-night salivary cortisol is a highly sensitive marker of hypercortisolism. This test is relatively convenient for patients (can be collected at home) and has good sensitivity and specificity when two samples are obtained and averaged.

24-Hour Urinary Free Cortisol: Urine is collected over a full 24-hour period, and the total free (unbound) cortisol excreted is measured. Because this reflects integrated cortisol production over the entire day, it is useful for confirming sustained hypercortisolism. Limitations include the inconvenience of 24-hour collection and the fact that mild or cyclical Cushing's syndrome may show normal results on some collections.

Step 3: Confirming Pathological Cortisol Elevation

If screening tests are abnormal, confirmatory testing is pursued. This may include:

• 2-day low-dose dexamethasone suppression test (LDDST): Dexamethasone 0.5 mg every 6 hours for 2 days, with cortisol measured at the end. More specific than the overnight test.
• Midnight serum cortisol: Requires hospital admission or precise timing; cortisol is measured at midnight when it should be lowest. Values above 7.5 μg/dL are strongly suggestive of Cushing's syndrome.
• Dex-CRH test (combined dexamethasone-CRH test): After LDDST, CRH is administered and cortisol/ACTH response is measured. Useful in differentiating Cushing's syndrome from pseudo-Cushing states.
• Desmopressin stimulation test: Desmopressin (DDAVP) stimulates ACTH secretion from pituitary corticotroph adenomas but not from normal pituitary corticotrophs.

A 2024 systematic review and meta-analysis published in PubMed (August 2024) — "The conundrum of differentiating Cushing's syndrome from non-neoplastic hypercortisolism" — compared the diagnostic accuracy of the Dex-CRH test, desmopressin stimulation, and midnight serum cortisol. The review found that all three had similar overall diagnostic accuracy, with Dex-CRH and midnight serum cortisol showing slightly higher sensitivity, while desmopressin demonstrated slightly higher specificity. This nuanced finding suggests that no single test is definitively superior, and that test selection should be individualized based on clinical context.

Step 4: Determining the Cause (Differential Diagnosis of Cushing's)

Once biochemical hypercortisolism is confirmed, the next challenge is determining the cause. This involves:

Plasma ACTH measurement:

• Suppressed or undetectable ACTH (< 10 pg/mL) → ACTH-independent (adrenal source)
• Normal or elevated ACTH (> 15 pg/mL) → ACTH-dependent (pituitary or ectopic source)

Imaging:

• Pituitary MRI (with gadolinium, high-resolution protocol) for suspected Cushing's disease — note that up to 40–50% of pituitary microadenomas may not be visualized even on high-quality MRI
• CT scan of the adrenal glands for ACTH-independent disease
• CT of chest, abdomen, and pelvis for suspected ectopic ACTH source

Inferior Petrosal Sinus Sampling (IPSS): The gold standard test for distinguishing Cushing's disease from ectopic ACTH syndrome when imaging is inconclusive. Catheters are placed in the inferior petrosal sinuses (which drain the pituitary) and ACTH levels are sampled simultaneously from both sides and from peripheral blood before and after CRH stimulation. A central-to-peripheral ACTH gradient ≥ 2 (basal) or ≥ 3 (post-CRH) confirms a pituitary ACTH source. Lateralization of the gradient can help guide the surgeon.

---

Which Cortisol Tests Are Most Accurate?

When it comes to Cushing's cortisol levels and testing accuracy, the evidence base has expanded considerably in recent years. The 2024 Endotext recommendations and the 2024 meta-analysis together paint a picture of a field where no single test is perfectly accurate, and where multi-test strategies are now standard practice.

Comparing the First-Line Tests

| Test | Sensitivity | Specificity | Key Advantages | Key Limitations | |---|---|---|---|---| | 1 mg Overnight DST | ~95–98% | ~75–80% | Easy, outpatient | High false-positive rate; affected by many medications | | Late-Night Salivary Cortisol | ~92–96% | ~93–100% | Home collection; detects loss of diurnal rhythm | Requires correct timing; smoking/contamination can affect results | | 24-Hour Urinary Free Cortisol | ~85–95% | ~94–98% | Reflects total daily production | Inconvenient; may miss mild/cyclical cases |

Hair Cortisol: An Emerging Biomarker

A particularly exciting development highlighted in the October 2024 PMC editorial "Insights in Cushing's Syndrome and Disease, Volume II" is the growing body of evidence supporting hair cortisol and cortisone measurement as a novel diagnostic tool. Hair grows approximately 1 cm per month, and cortisol is incorporated into the hair shaft as it grows. This means that measuring cortisol in a 3 cm segment of hair provides a 3-month retrospective window of cortisol exposure — a fundamentally different type of information than any other currently available test.

Hair cortisol testing has shown particular promise for:

• Diagnosing cyclical Cushing's syndrome, where cortisol levels fluctuate and may be normal during standard testing windows
• Providing a long-term integrated measure that is less susceptible to the acute fluctuations that confound serum, salivary, and urinary tests
• Monitoring treatment response over time

While hair cortisol is not yet a standard first-line test and lacks universal cutoffs, it represents one of the most clinically relevant innovations in Cushing's syndrome research in recent years.

Saliva vs. Serum: Practical Considerations

Late-night salivary cortisol has become increasingly favored in clinical practice because of its non-invasive nature and the ability for patients to collect samples at home, which eliminates the stress-related cortisol elevation that can occur with hospital-based blood draws at midnight. However, it requires careful patient instructions — patients must avoid eating, drinking (except water), brushing teeth, or using oral tobacco for at least 30 minutes before collection, and they should collect samples using standardized collection devices.

Midnight serum cortisol, when performed correctly (typically requiring overnight hospital observation to ensure the patient is in a relaxed, undisturbed state), remains one of the most specific single measures for Cushing's syndrome, with values above 7.5 μg/dL (207 nmol/L) considered strongly indicative.

---

Risks of Untreated High Cortisol: What the Research Shows

The consequences of untreated Cushing's syndrome — sustained pathological cortisol elevation — are severe, progressive, and ultimately life-threatening. Understanding these risks reinforces why early diagnosis is so critical and why Cushing's syndrome research continues to attract significant scientific investment.

Cardiovascular Disease

Chronic hypercortisolism promotes an atherogenic environment through multiple mechanisms: it drives visceral obesity, induces dyslipidemia, promotes insulin resistance and hyperglycemia, and directly contributes to hypertension through mineralocorticoid-like effects on renal sodium retention and increased vascular sensitivity to vasoconstrictors. Patients with active Cushing's syndrome have dramatically elevated rates of cardiovascular events, including myocardial infarction and stroke, compared to age-matched controls.

Even after biochemical remission, cardiovascular risk does not immediately normalize. Studies have shown that patients who have been cured of Cushing's syndrome retain elevated cardiovascular risk for years afterward, emphasizing the importance of long-term cardiovascular monitoring and aggressive risk factor management.

Metabolic Complications

Cortisol is a counter-regulatory hormone that directly opposes insulin. Chronic cortisol excess leads to:

• Impaired glucose tolerance in mild cases
• Frank type 2 diabetes mellitus in sustained hypercortisolism
• Metabolic syndrome encompassing central obesity, hypertension, dyslipidemia, and hyperglycemia
• Non-alcoholic fatty liver disease through visceral fat accumulation and hepatic glucose dysregulation

A 2025 PMC study published in April 2025 — "The impact of prolonged high-concentration cortisol exposure in Cushing's disease" — provided further mechanistic evidence of how sustained cortisol excess at high concentrations produces cumulative organ-level damage that extends well beyond the period of active hypercortisolism.

Skeletal Complications

Cortisol suppresses osteoblast function (bone formation) while promoting osteoclast activity (bone resorption), creating a net negative effect on bone density. This leads to:

• Osteoporosis — often severe and disproportionate to what would be expected from the patient's age
• Vertebral compression fractures — can occur spontaneously or with minimal trauma
• Rib fractures
• Avascular necrosis — particularly of the femoral head

The skeletal consequences of Cushing's syndrome can be particularly devastating in younger patients who have not yet reached peak bone mass.

Neuropsychiatric Consequences

Cortisol receptors are expressed throughout the brain, and the hippocampus — a brain region critical for memory formation and emotional regulation — is particularly vulnerable to glucocorticoid excess. Chronic hypercortisolism leads to:

• Hippocampal atrophy — measurable by volumetric MRI studies
• Cognitive impairment — particularly declarative memory deficits
• Major depression — present in up to 50–80% of patients with active Cushing's syndrome
• Increased risk of suicide
• Post-remission neuropsychiatric sequelae — cognitive and mood impairments may persist for years after biochemical cure

Immune Dysregulation

Sustained cortisol excess profoundly suppresses immune function. Patients with active Cushing's syndrome are at significantly increased risk for:

• Bacterial infections (particularly skin, urinary tract, and respiratory)
• Fungal infections (including opportunistic infections like Pneumocystis jirovecii pneumonia in severe cases)
• Impaired wound healing and surgical recovery
• Reactivation of latent infections (e.g., tuberculosis, herpes zoster)

Mortality

Untreated Cushing's syndrome has historically been associated with a 5-year mortality rate of approximately 50%, primarily from cardiovascular disease and infections. Even with modern treatment, achieving and maintaining biochemical remission are essential for improving this prognosis. Persistent or recurrent hypercortisolism after initial treatment carries a significantly worse long-term outlook.

---

---

Treatment Options for Cushing's Syndrome

The treatment of Cushing's syndrome is guided entirely by the underlying cause. There is no "one-size-fits-all" approach to managing cortisol disease excess — the source must be identified and targeted specifically.

Surgical Approaches

Transsphenoidal Surgery (for Cushing's Disease) The first-line and preferred treatment for Cushing's disease is transsphenoidal adenomectomy — surgical removal of the ACTH-secreting pituitary adenoma via a minimally invasive approach through the nose and sphenoid sinus. When performed by an experienced pituitary neurosurgeon at a high-volume center, initial remission rates are 65–90% for microadenomas. Recurrence rates are significant, however, with studies showing that up to 25–30% of patients will experience recurrence over 10 years.

Adrenalectomy (for Adrenal Tumors) For ACTH-independent Cushing's syndrome caused by an adrenal adenoma or carcinoma, surgical removal of the affected adrenal gland (adrenalectomy) is the treatment of choice. Laparoscopic adrenalectomy for benign adenomas carries excellent outcomes with minimal morbidity.

For adrenal carcinoma, surgery is combined with adjuvant treatment (mitotane, chemotherapy) given the high recurrence rates.

Bilateral Adrenalectomy When other treatments have failed or are not feasible (including in severe ectopic ACTH syndrome when the primary tumor cannot be found or resected), bilateral adrenalectomy is a definitive option for controlling hypercortisolism. It guarantees permanent cure of hypercortisolism but requires lifelong glucocorticoid and mineralocorticoid replacement therapy (adrenal insufficiency). A rare complication is Nelson's Syndrome — aggressive growth of the pituitary adenoma after bilateral adrenalectomy due to loss of cortisol feedback on ACTH secretion, leading to very high ACTH levels and hyperpigmentation.

Radiation Therapy

Pituitary Radiation (for Cushing's Disease) When transsphenoidal surgery fails or is not possible, pituitary radiation can be used to reduce ACTH secretion. Options include:

• Stereotactic radiosurgery (Gamma Knife, CyberKnife) — delivers a high dose in a single session; remission rates of 50–70% but with a delay of 12–60 months before full effect
• Fractionated radiotherapy — lower per-session dose, delivered over multiple sessions; lower rates of immediate hypopituitarism but longer time to remission

Radiation therapy is often used as a bridge with medical therapy until its full cortisol-lowering effect is achieved.

Medical Therapy

Medical management of hypercortisolism has traditionally been used as:

• A bridge to surgery or radiation
• Treatment while awaiting the effect of radiation therapy
• Long-term management when surgery is not possible or has failed

A 2025 PubMed review published in July 2025 — "Advances in the medical management of hypercortisolism" — provided a comprehensive overview of the pharmacologic landscape for endogenous Cushing's syndrome, highlighting both established and newer agents.

Steroidogenesis Inhibitors (act on the adrenal glands):

• Metyrapone — inhibits 11β-hydroxylase, a key enzyme in cortisol synthesis; fast-acting and effective; may cause hirsutism and hypokalemia
• Ketoconazole — inhibits multiple steroidogenic enzymes; hepatotoxicity risk requires monitoring
• Osilodrostat (Isturisa) — a newer, highly potent 11β-hydroxylase inhibitor approved specifically for Cushing's disease where surgery has failed or is not appropriate; associated with elevated androgens in women
• Mitotane — adrenolytic agent; used primarily for adrenocortical carcinoma; slow onset and significant side effects
• Levoketoconazole — an R-enantiomer of ketoconazole with improved tolerability; approved for Cushing's syndrome in adults

Pituitary-Directed Agents (for Cushing's Disease):

• Pasireotide (Signifor) — a somatostatin receptor ligand that suppresses ACTH secretion from pituitary adenomas; effective in 20–25% of patients; significant risk of hyperglycemia due to its effects on pancreatic insulin secretion
• Cabergoline — a dopamine agonist that can suppress ACTH in some Cushing's disease patients; generally well-tolerated

Glucocorticoid Receptor Antagonists:

• Mifepristone (Korlym) — blocks the glucocorticoid receptor, preventing cortisol from exerting its clinical effects; approved for Cushing's syndrome in patients with type 2 diabetes or glucose intolerance who have failed surgery; does not lower cortisol levels (which paradoxically rise), making monitoring challenging

Managing Exogenous/Iatrogenic Cushing's Syndrome

For iatrogenic Cushing's syndrome caused by prescribed glucocorticoids, the treatment is gradual tapering and discontinuation (where medically safe) of the offending glucocorticoid, with substitution of non-glucocorticoid immunosuppressive agents where possible. This must be done carefully to avoid precipitating adrenal insufficiency in patients whose HPA axis has been suppressed.

---

Can Stress Alone Cause Cushing's Syndrome?

This is one of the most common questions patients and concerned individuals ask when they learn that cortisol is the "stress hormone." The short answer is: no, psychological stress alone cannot cause Cushing's syndrome as a clinical disease, but the relationship is more nuanced than this simple answer suggests.

Physiological Stress Response vs. Pathological Cortisol Elevation

During acute psychological or physical stress, the HPA axis activates, CRH is released, ACTH rises, and cortisol levels increase — sometimes substantially. This is a normal, adaptive response designed to mobilize energy, heighten alertness, and prepare the body for action. In healthy individuals, this stress response is self-limiting: once the stressor resolves, negative feedback mechanisms restore cortisol to baseline levels within hours.

For cortisol elevation to produce the syndrome of Cushing's syndrome, exposure must be:

• Prolonged — sustained over weeks to months, not hours
• Unregulated — occurring outside normal negative feedback control
• Pathologically elevated — reaching levels substantially above the normal stress response range

Psychological stress, even when chronic, does not produce the autonomous, unregulated, feedback-resistant cortisol elevation that characterizes true Cushing's syndrome. The HPA axis in chronically stressed individuals remains responsive to negative feedback; it is overactive but not fully autonomous.

Pseudo-Cushing's States

However, there is a clinically important category called pseudo-Cushing's states, in which certain conditions can produce mild to moderate biochemical hypercortisolism and even some clinical features resembling Cushing's syndrome, without there being a discrete tumor or pathological HPA axis lesion. Conditions associated with pseudo-Cushing's include:

• Severe major depressive disorder — activates the HPA axis, can cause elevated urinary free cortisol and non-suppression on DST
• Alcoholism — alcohol stimulates CRH secretion and can produce cortisol excess
• Morbid obesity — can produce mild HPA axis dysregulation
• Uncontrolled type 2 diabetes
• Chronic severe illness

Distinguishing true Cushing's syndrome from pseudo-Cushing's states is one of the most diagnostically challenging problems in endocrinology. The Dex-CRH test was specifically developed to help make this distinction — in pseudo-Cushing's states, the cortisol response is typically suppressed after the dexamethasone/CRH combination, whereas true Cushing's syndrome shows an exaggerated ACTH and cortisol response.

---

Emerging Research in Cushing's Syndrome (2024–2025)

Cushing's syndrome research has been notably productive in the 2024–2025 period, with advances spanning diagnostic methodology, pharmacological management, and mechanistic understanding of cortisol excess disease.

2024: Rapid Evidence Review of Diagnosis and Management

A September 2024 PubMed review titled "Cushing's Syndrome: Rapid Evidence Review" provided a concise, updated synthesis of clinical evidence on diagnosis and management. The review reinforced the multi-test diagnostic approach and highlighted the ongoing challenges in distinguishing mild or cyclical Cushing's syndrome from pseudo-Cushing's states using conventional biochemical tools. It also summarized the growing body of evidence supporting minimally invasive pituitary surgery as the gold standard for Cushing's disease when performed at specialized centers.

2024: Diagnostic Test Accuracy Meta-Analysis

The August 2024 systematic review — "The conundrum of differentiating Cushing's syndrome from non-neoplastic hypercortisolism: a systematic review and meta-analysis" — provided the most comprehensive head-to-head comparison of Dex-CRH, desmopressin stimulation, and midnight serum cortisol to date. The finding that all three tests have similar but not identical diagnostic performance profiles has practical implications: rather than recommending one test as universally superior, the evidence supports a individualized approach where the choice of confirmatory test is guided by patient characteristics, local expertise, and pre-test probability.

2024: Advances in Diagnostic Biomarkers

The October 2024 PMC editorial "Insights in Cushing's Syndrome and Disease, Volume II" discussed several emerging diagnostic approaches that could transform clinical practice:

Hair Cortisol and Cortisone Measurement: As discussed earlier, hair-based cortisol testing provides a retrospective 3-month window of cortisol exposure. The 2024 editorial highlighted growing evidence that hair cortisol is particularly valuable for detecting cyclical or intermittent hypercortisolism — a form of Cushing's syndrome that is notoriously difficult to capture with conventional spot or short-duration tests. Hair cortisone (the inactive metabolite) may even outperform hair cortisol in some contexts.

Advanced Imaging Techniques: The editorial also discussed improvements in pituitary imaging, including the use of high-resolution 3T MRI protocols, spoiled gradient-echo sequences, and artificial intelligence-assisted lesion detection to improve visualization of small microadenomas that previously evaded detection. Additionally, functional imaging with 11C-methionine PET and 68Ga-DOTATATE PET are showing promise for detecting ectopic ACTH-secreting tumors that are occult on conventional CT and MRI.

2025: Advances in Medical Management

The July 2025 PubMed review "Advances in the medical management of hypercortisolism" represented the most current synthesis of pharmacological approaches, reflecting the expanding therapeutic armamentarium for endogenous Cushing's syndrome. Key themes included:

• Osilodrostat and levoketoconazole have now accumulated more real-world experience since their approvals, with emerging data on long-term efficacy and safety profiles
• Combination pharmacotherapy — using agents with complementary mechanisms (e.g., combining a steroidogenesis inhibitor with a pituitary-directed agent) — is being studied as a strategy to achieve more complete cortisol control while minimizing the side effects of individual high-dose therapy
• Biomarker-guided dosing strategies are being explored to improve the precision of cortisol-lowering therapies and reduce the risk of adrenal insufficiency from over-treatment

2025: Long-Term Effects of Cortisol Excess

The April 2025 PMC study "The impact of prolonged high-concentration cortisol exposure" contributed important mechanistic data on how sustained cortisol excess at disease-relevant concentrations produces cumulative damage at the cellular and organ levels. This research has implications not just for understanding Cushing's disease progression, but also for understanding the persistence of complications after biochemical remission — a phenomenon sometimes called the "cortisol memory" effect, in which metabolic, skeletal, and neuropsychiatric consequences persist long after cortisol levels normalize.

---

---

Frequently Asked Questions

What is the difference between Cushing's syndrome and Cushing's disease?

Cushing's syndrome is the broader term for any condition causing prolonged cortisol excess, regardless of the cause — including medications, adrenal tumors, ectopic ACTH production, or pituitary tumors. Cushing's disease specifically refers to Cushing's syndrome caused by an ACTH-secreting pituitary adenoma. All cases of Cushing's disease are Cushing's syndrome, but not all cases of Cushing's syndrome are Cushing's disease.

What causes high cortisol besides steroid medications?

High cortisol can also be caused by endogenous sources including ACTH-secreting pituitary adenomas (Cushing's disease), cortisol-secreting adrenal tumors (adenoma or carcinoma), ectopic ACTH production from non-pituitary tumors (commonly small cell lung carcinoma or carcinoid tumors), and rare conditions like ACTH-independent macronodular adrenal hyperplasia. Pseudo-Cushing's states from severe depression, alcoholism, or morbid obesity can also produce mild cortisol elevation.

What are the first symptoms of Cushing's syndrome?

Early symptoms are often nonspecific and include weight gain (particularly in the trunk), fatigue, mood changes (depression, irritability, anxiety), sleep disturbances, and hypertension. More distinctive features that develop over time include central obesity, moon face, buffalo hump, purple striae, easy bruising, proximal muscle weakness, and menstrual irregularities in women.

How is Cushing's syndrome diagnosed?

Diagnosis involves a multi-step approach: biochemical screening with one or more of the recommended first-line tests (1 mg overnight dexamethasone suppression test, late-night salivary cortisol, 24-hour urinary free cortisol), followed by confirmatory testing if screening is positive, and then determination of the underlying cause using plasma ACTH measurement, imaging studies, and specialized tests like inferior petrosal sinus sampling.

Which cortisol tests are most accurate?

According to the 2024 meta-analysis, the Dex-CRH test, desmopressin stimulation, and midnight serum cortisol all have similar overall diagnostic accuracy. For screening, late-night salivary cortisol has excellent sensitivity and specificity when performed correctly. No single test is perfectly accurate in all clinical contexts, and guidelines recommend using at least two different tests for initial screening and confirmation.

Can stress alone cause Cushing's syndrome?

No. While psychological stress activates the HPA axis and temporarily elevates cortisol, this response remains regulated by normal negative feedback mechanisms and does not produce the sustained, autonomous, pathologically elevated cortisol characteristic of Cushing's syndrome. However, severe depression, alcoholism, and other conditions can produce pseudo-Cushing's states with mild biochemical hypercortisolism that can sometimes be difficult to distinguish from early Cushing's syndrome.

Is Cushing's syndrome curable?

Yes, in many cases Cushing's syndrome can be cured, particularly when the cause is a resectable tumor. For Cushing's disease, successful transsphenoidal surgery achieves remission in 65–90% of cases with microadenomas at experienced centers. For adrenal adenomas, adrenalectomy is usually curative. However, Cushing's disease recurs in up to 25–30% of patients over 10 years, and some patients require repeat surgery, radiation, or long-term medical therapy.

How is Cushing's syndrome treated in 2024–2026 practice?

Treatment in current practice is highly individualized based on cause. For Cushing's disease, transsphenoidal surgery remains first-line, followed by radiation and/or medical therapy (pasireotide, osilodrostat, cabergoline, metyrapone, ketoconazole, levoketoconazole) for persistent or recurrent cases. For adrenal tumors, adrenalectomy is the primary treatment. The 2025 review on advances in medical management highlighted growing use of combination pharmacotherapy and biomarker-guided dosing approaches.

What are the risks of untreated high cortisol?

Untreated hypercortisolism carries severe risks including cardiovascular disease (hypertension, dyslipidemia, increased risk of heart attack and stroke), metabolic syndrome and diabetes, osteoporosis with pathological fractures, neuropsychiatric complications (depression, cognitive impairment), immune suppression, and increased infection risk. Historically, untreated Cushing's syndrome carried a 5-year mortality rate of approximately 50%.

How do pituitary and adrenal causes of Cushing's syndrome differ?

Pituitary causes (Cushing's disease) are ACTH-dependent — the adrenal glands are being driven to overproduce cortisol by excessive ACTH from a pituitary adenoma. Both adrenal glands are typically enlarged (bilateral adrenal hyperplasia). Adrenal causes are ACTH-independent — the adrenal tumor produces cortisol autonomously, suppressing ACTH levels. Only one adrenal gland is usually affected in adenoma or carcinoma, and the other adrenal gland atrophies due to the low ACTH. This distinction is made clinically through plasma ACTH measurement.

---

Key Takeaways

Understanding the cortisol and Cushing's syndrome science requires integrating knowledge of normal HPA axis physiology, the mechanisms by which this system can be disrupted, the multi-system consequences of cortisol excess disease, and the evolving diagnostic and therapeutic landscape. Here are the essential points from this comprehensive review:

1. Cushing's syndrome is defined by prolonged exposure to excess cortisol, whether from exogenous glucocorticoids (>99% of all cases) or endogenous sources (2–8 per million annually for the endogenous form).

1. Cushing's disease is a specific subtype of Cushing's syndrome caused by an ACTH-secreting pituitary adenoma — the most common endogenous cause, accounting for 70–80% of endogenous ACTH-dependent cases.

1. The Cushing's HPA axis — when disrupted — produces autonomous or semi-autonomous cortisol excess that bypasses the normal negative feedback mechanisms governing cortisol production.

1. Pathological cortisol elevation produces a characteristic constellation of symptoms including central obesity, moon face, purple striae, proximal myopathy, osteoporosis, hypertension, hyperglycemia, and neuropsychiatric disorders — but early presentations are often nonspecific.

1. First-line diagnostic screening per 2024 Endotext guidelines includes the 1 mg overnight dexamethasone suppression test, late-night salivary cortisol (minimum 2 samples), and 24-hour urinary free cortisol (minimum 2 collections).

1. 2024 meta-analysis data show that Dex-CRH, desmopressin stimulation, and midnight serum cortisol have similar diagnostic accuracy, with subtle differences in sensitivity and specificity that should guide individualized test selection.

1. Emerging biomarkers including hair cortisol and cortisone measurement, and advanced imaging techniques, are showing promise for diagnosing difficult cases including cyclical hypercortisolism.

1. Treatment is cause-specific: surgery is first-line for most tumor-related causes; radiation and pharmacotherapy are adjunctive or alternative strategies. The 2025 pharmacology review highlights expanding medical options including osilodrostat, levoketoconazole, and combination approaches.

1. Untreated hypercortisolism carries a historically high mortality rate driven by cardiovascular, metabolic, skeletal, and infectious complications — and many complications persist even after biochemical remission.

1. Stress alone cannot cause Cushing's syndrome, but pseudo-Cushing's states from severe depression, alcoholism, or obesity can mimic its biochemical profile and require careful clinical differentiation.

---

References and Sources

• PubMed. "Cushing Syndrome: A Review." Published 2023. PMID available at PubMed.gov.
• Medscape. Cushing Syndrome Overview. Updated 2024.
• Endotext. Cushing's Syndrome Diagnosis and Treatment. Updated 2024. Available at: endotext.org
• PubMed. "The conundrum of differentiating Cushing's syndrome from non-neoplastic hypercortisolism: a systematic review and meta-analysis." August 2024.
• PMC. "Editorial: Insights in Cushing's syndrome and disease, volume II." October 2024. PMC.
• PubMed. "Cushing's Syndrome: Rapid Evidence Review." September 2024.
• PubMed. "Advances in the medical management of hypercortisolism." July 2025.
• PMC. "The impact of prolonged high-concentration cortisol exposure in Cushing's disease." April 2025.
• NIDDK. Cushing's Syndrome. Available at: niddk.nih.gov
• Mayo Clinic. Cushing Syndrome — Symptoms and Causes. Available at: mayoclinic.org
• NCBI Bookshelf. StatPearls: Cushing Syndrome. Available at: ncbi.nlm.nih.gov/books/NBK279088/
• JAMA. Clinical Review: Cushing's Syndrome Diagnosis and Management.

---

This article is intended for educational purposes only. It does not constitute medical advice. If you have concerns about cortisol excess or symptoms that may suggest Cushing's syndrome, please consult a board-certified endocrinologist or your primary care physician. Early diagnosis and appropriate specialist referral are critical for the best possible outcomes.